Exact Mass: 341.2272242
Exact Mass Matches: 341.2272242
Found 111 metabolites which its exact mass value is equals to given mass value 341.2272242,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Pregnenolone carbonitrile
5-Hydroxymethyl tolterodine
5-Hydroxymethyl tolterodine is only found in individuals that have used or taken tolterodine. 5-Hydroxymethyl tolterodine is a metabolite of tolterodine. 5-Hydroxymethyl tolterodine belongs to the family of Diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.
Diprotin A
C17H31N3O4 (341.23144460000003)
Pregnenolone carbonitrile
(8S,9S,10S,13S,14S,17S)-17-Acetyl-3-hydroxy-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-1-carbonitrile
Leu-Pro-Ile
C17H31N3O4 (341.23144460000003)
Deoxycalyciphylline B
18-methylaminoavarone|2-Methylaminoavarone|3-methylaminoavarone
(E)-3,7-dimethylocta-2,6-dienyl 2-(3-methylbut-2-enylamino)benzoate|geranyl N-dimethylallylanthranilate
(2E,4E,10E)-N-isobutyl-11-(4-methoxyphenyl)undeca-2,4,10-trienamide|philippinamide
MLS002207185-01!Ile-Pro-Ile90614-48-5
C17H31N3O4 (341.23144460000003)
Diprotin A
C17H31N3O4 (341.23144460000003)
D007004 - Hypoglycemic Agents > D054873 - Dipeptidyl-Peptidase IV Inhibitors D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors Diprotin A (Ile-Pro-Ile) is an inhibitor of dipeptidyl peptidase IV (DPP-IV)[1].
5-Hydroxymethyltolterodine
Desfesoterodine (PNU-200577) is a potent and selective muscarinic receptor (mAChR) antagonist with a KB and a pA2 of 0.84 nM and 9.14, respectively[1]. Desfesoterodine is a major pharmacologically active metabolite of Tolterodine (PNU-200583; HY-A0024) and Fesoterodine (HY-70053)[2][3]. Desfesoterodine improves cerebral infarction induced detrusor overactivity in rats[4].
(Rac)-5-Hydroxymethyl Tolterodine
(Rac)-5-Hydroxymethyl Tolterodine ((Rac)-Desfesoterodine), an active metabolite of Tolterodine, is a mAChR antagonist (Ki values of 2.3 nM, 2 nM, 2.5 nM, 2.8 nM, and 2.9 nM for M1, M2, M3, M4, and M5 receptors, respectively). (Rac)-5-Hydroxymethyl Tolterodine can be used for overactive bladder research[1].
(E)-16-(carboxymethylamino)-4-oxohexadec-11-enoic acid
4-[3-(1-Imidazolyl)proplyaminomethyl]benzeneboronic acid pinacol ester
(3-chloro-2-hydroxypropyl)dodecyldimethylammonium chloride
2-di-t-butylphosphino-2-(n,n-dimethylamino)biphenyl
n-(1-Adamantyl)-n-(4-guanidinobenzyl)urea
C19H27N5O (341.22154919999997)
17-acetyl-3-hydroxy-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-16-carbonitrile
Desfesoterodine
G - Genito urinary system and sex hormones > G04 - Urologicals > G04B - Urologicals > G04BD - Drugs for urinary frequency and incontinence C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent Desfesoterodine (PNU-200577) is a potent and selective muscarinic receptor (mAChR) antagonist with a KB and a pA2 of 0.84 nM and 9.14, respectively[1]. Desfesoterodine is a major pharmacologically active metabolite of Tolterodine (PNU-200583; HY-A0024) and Fesoterodine (HY-70053)[2][3]. Desfesoterodine improves cerebral infarction induced detrusor overactivity in rats[4].
2-{[1-(2-Amino-3-methyl-pentanoyl)-pyrrolidine-2-carbonyl]-amino}-3-methyl-pentanoic acid
C17H31N3O4 (341.23144460000003)
1-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3-oxanyl]-3-propan-2-ylurea
C17H31N3O4 (341.23144460000003)
1-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3-oxanyl]-3-propan-2-ylurea
C17H31N3O4 (341.23144460000003)
1-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3-oxanyl]-3-propan-2-ylurea
C17H31N3O4 (341.23144460000003)
1-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3-oxanyl]-3-propan-2-ylurea
C17H31N3O4 (341.23144460000003)
1-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3-oxanyl]-3-propan-2-ylurea
C17H31N3O4 (341.23144460000003)
1-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3-oxanyl]-3-propan-2-ylurea
C17H31N3O4 (341.23144460000003)
methylglyoxal-lysine dimer
An imidazolium ion formed via cyclo-dimerisation of L-lysine and methylglyoxal.
CB2R/FAAH modulator-3
CB2R/FAAH modulator-3 (compound 27) is a dual targeting modulator that acts as a CB2R agonist and FAAH inhibitor. The Ki values for CB2R/FAAH modulator-3 are 20.1 and 67.6 nM for CB2R and CB1R, respectively, and the IC50 value for FAAH is 3.4 μM. CB2R/FAAH modulator-3 can be used in studies related to cancer, deleterious inflammatory cascades occurring in neurodegenerative diseases, and COVID-19 infection[1].
(1s,7s,10s,11r,15r,22r,23r)-11-methyl-5-oxa-13-azahexacyclo[11.9.1.0¹,⁷.0⁷,¹⁵.0¹⁰,²³.0¹⁸,²²]tricos-18-en-4-one
(1s,2r,3r,5s,8r,9s,10r,13r,17r)-11-ethyl-8-hydroxy-13-methyl-4-methylidene-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-16-one
(5z,8z,11z)-n-[2-(4-hydroxyphenyl)ethyl]tetradeca-5,8,11-trienimidic acid
(1s,6r,7s,10r,15r,19r,22s)-6,18-dimethyl-5-oxa-16-azahexacyclo[14.5.1.0¹,⁶.0⁷,¹⁵.0¹⁰,¹⁴.0¹⁹,²²]docos-13-en-4-one
(1r,7r,10r,11s,15s,18s,23s)-11-methyl-5-oxa-13-azahexacyclo[11.9.1.0¹,⁷.0⁷,¹⁵.0¹⁰,²³.0¹⁸,²²]tricos-21-en-4-one
(2s,3s)-2-({[(2s)-1-[(2s,3s)-2-amino-3-methylpentanoyl]pyrrolidin-2-yl](hydroxy)methylidene}amino)-3-methylpentanoic acid
C17H31N3O4 (341.23144460000003)
(2r,3z,12bs)-3-ethylidene-2-(2-hydroxyethyl)-9-methoxy-5-methyl-1h,2h,4h,6h,7h,12h,12bh-indolo[2,3-a]quinolizin-5-ium
11-ethyl-8-hydroxy-13-methyl-4-methylidene-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-16-one
(2e,4e,10e)-11-(4-methoxyphenyl)-n-(2-methylpropyl)undeca-2,4,10-trienimidic acid
(1s,6r,7s,10s,15r,18s,19r,22s)-6,18-dimethyl-5-oxa-16-azahexacyclo[14.5.1.0¹,⁶.0⁷,¹⁵.0¹⁰,¹⁴.0¹⁹,²²]docos-13-en-4-one
(1r,7r,10r,11s,15s,18r,23s)-11-methyl-5-oxa-13-azahexacyclo[11.9.1.0¹,⁷.0⁷,¹⁵.0¹⁰,²³.0¹⁸,²²]tricos-21-en-4-one
n-[2-(4-hydroxyphenyl)ethyl]tetradeca-5,8,11-trienimidic acid
(1s,2s,3s,5r,8s,9s,10r,13r,17r)-11-ethyl-8-hydroxy-13-methyl-4-methylidene-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-16-one
(1s,6s,7s,10s,15r,18s,19r,22s)-6,18-dimethyl-5-oxa-16-azahexacyclo[14.5.1.0¹,⁶.0⁷,¹⁵.0¹⁰,¹⁴.0¹⁹,²²]docos-13-en-4-one
(1r,7r,10r,11r,15s,18r,23r)-11-methyl-5-oxa-13-azahexacyclo[11.9.1.0¹,⁷.0⁷,¹⁵.0¹⁰,²³.0¹⁸,²²]tricos-21-en-4-one
2-{[(1r,2s,4as)-1,2,4a,5-tetramethyl-2,3,4,7,8,8a-hexahydronaphthalen-1-yl]methyl}-5-(methylamino)cyclohexa-2,5-diene-1,4-dione
(1s,2s,5s,6s,9r,11r,12s,13r)-11-hydroxy-6,7,13-trimethyl-7-azapentacyclo[10.8.0.0²,⁹.0⁵,⁹.0¹³,¹⁸]icosa-14,17-dien-16-one
11-methyl-5-oxa-13-azaheptacyclo[11.9.1.0¹,⁷.0⁷,¹⁵.0¹⁰,²³.0¹⁴,¹⁸.0¹⁸,²²]tricosan-4-one
(6r,7s,10s,15r,18s,19r,22s)-6,18-dimethyl-5-oxa-16-azahexacyclo[14.5.1.0¹,⁶.0⁷,¹⁵.0¹⁰,¹⁴.0¹⁹,²²]docos-13-en-4-one
11-(4-methoxyphenyl)-n-(2-methylpropyl)undeca-2,4,10-trienimidic acid
(1r,7r,10r,14s,15s,22r)-11-methyl-5-oxa-13-azaheptacyclo[11.9.1.0¹,⁷.0⁷,¹⁵.0¹⁰,²³.0¹⁴,¹⁸.0¹⁸,²²]tricosan-4-one
(1r,7r,10r,11s,14r,15s,18r,22r,23s)-11-methyl-5-oxa-13-azaheptacyclo[11.9.1.0¹,⁷.0⁷,¹⁵.0¹⁰,²³.0¹⁴,¹⁸.0¹⁸,²²]tricosan-4-one
11-methyl-5-oxa-13-azahexacyclo[11.9.1.0¹,⁷.0⁷,¹⁵.0¹⁰,²³.0¹⁸,²²]tricos-21-en-4-one
11-methyl-5-oxa-13-azahexacyclo[11.9.1.0¹,⁷.0⁷,¹⁵.0¹⁰,²³.0¹⁸,²²]tricos-18-en-4-one
2-({[1-(2-amino-3-methylpentanoyl)pyrrolidin-2-yl](hydroxy)methylidene}amino)-3-methylpentanoic acid
C17H31N3O4 (341.23144460000003)